AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19843655 — intervention group
Group type: EXPERIMENTAL
Intervention: Perphenazine in nonsmoking other races
Number of subjects: 156
Study 19843655 — intervention group
Group type: EXPERIMENTAL
Intervention: Perphenazine in active smokers
Number of subjects: 156
Study 19843655 — intervention group
Group type: EXPERIMENTAL
Intervention: Perphenazine in smoking African Americans
Number of subjects: 156
Study 19843655 — intervention group
Group type: EXPERIMENTAL
Intervention: Perphenazine in smokers of other races
Number of subjects: 156
Study 17506736 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine alone (1 ml of 0.25% bupivacaine on each side)
Number of subjects: 40
Study 17506736 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine with pethidine (1 ml of 0.25% bupivacaine and 0.25 mg.kg(‐1) body weight pethidine)
Number of subjects: 40
Study 15652871 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal urinary excretion of 6‐sulphatoxymelatonin in patients with autism
Number of subjects: 49
Study 15652871 — intervention group
Group type: COMPARATOR
Intervention: Normal control individuals (matched on age, sex, and Tanner stage)
Number of subjects: 49
Study 11308250 — intervention group
Group type: EXPERIMENTAL
Intervention: DTIC (850 mg/m² every 28 days) plus IFN-alpha2a/b (3 MIU/m², twice on day 1, once daily from days 2 to 5; 5 MIU/m² 3 times a week from week 2 to 4)
Number of subjects: 290
Study 11308250 — intervention group
Group type: COMPARATOR
Intervention: DTIC (850 mg/m² every 28 days) plus IFN-alpha2a/b (3 MIU/m², twice on day 1, once daily from days 2 to 5; 5 MIU/m² 3 times a week from week 2 to 4) plus IL-2 (4.5 MIU/m² for 3 hours i.v. on day 3; 9.0 MIU/m² i.v. day 3/4; 4.5 MIU/m² s.c. days 4 to 7)
Number of subjects: 290
Study 9447531 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant dosing through a proximal sideport adapter
Number of subjects: 36
Study 9447531 — intervention group
Group type: COMPARATOR
Intervention: Surfactant dosing through a double-lumen endotracheal tube
Number of subjects: 36
Study 7543288 — intervention group
Group type: EXPERIMENTAL
Intervention: 153Sm‐EDTMP (330 MBq to 1110 MBq)
Number of subjects: 35
Study 3065744 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha 2b Interferon
Number of subjects: 34
Study 3065744 — intervention group
Group type: COMPARATOR
Intervention: Control (non-treated)
Number of subjects: 34
Study 2405806 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine hydrochloride treatment
Number of subjects: 0
Study 2405806 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study 2405806 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine treatment combined with intensive group psychotherapy
Number of subjects: 0
Study 2405806 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment combined with intensive group psychotherapy
Number of subjects: 0
Study 339672 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide
Number of subjects: 59
Study 339672 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenoxylate
Number of subjects: 59
Study 339672 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 30824256 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU+APP (treatment as usual with app access)
Number of subjects: 129
Study 30824256 — intervention group
Group type: COMPARATOR
Intervention: TAU (treatment as usual without app access)
Number of subjects: 129
Study 27805273 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser
Number of subjects: 24
Study 27805273 — intervention group
Group type: COMPARATOR
Intervention: Bipolar radiofrequency combined with diode laser (BRDL)
Number of subjects: 24
Study 25494297 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-iodine-load protocol (400 mg iodine per kg at 80 kVp)
Number of subjects: 113
Study 25494297 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-iodine-load protocol (400 mg iodine per kg at 80 kVp)
Number of subjects: 113
Study 25494297 — intervention group
Group type: COMPARATOR
Intervention: High-iodine-load protocol (600 mg iodine per kg at 120 kVp)
Number of subjects: 113
Study 25494297 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-iodine-load protocol
Number of subjects: 113
Study 25494297 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-iodine-load protocol
Number of subjects: 113
Study 23274606 — intervention group
Group type: EXPERIMENTAL
Intervention: PACER test
Number of subjects: 45
Study 23274606 — intervention group
Group type: COMPARATOR
Intervention: Treadmill GXT
Number of subjects: 45
Study 21299845 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous darbepoetin infusion and intracoronary infusion of peripheral blood stem cells mobilized with G‐CSF (n = 58)
Number of subjects: 116
Study 21299845 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of peripheral blood stem cells mobilized with G‐CSF alone (n = 29)
Number of subjects: 116
Study 21299845 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (n = 29)
Number of subjects: 116
Study 19741605 — intervention group
Group type: EXPERIMENTAL
Intervention: native E. coli asparaginase
Number of subjects: 40
Study 19741605 — intervention group
Group type: COMPARATOR
Intervention: PEG asparaginase
Number of subjects: 40
Study 16758918 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronopuncture as a non-drug method of arterial pressure correction
Number of subjects: 0
Study 14691440 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol treatment
Number of subjects: 27
Study 14691440 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (placebo group)
Number of subjects: 27
Study 11340718 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride mouthrinse
Number of subjects: 414
Study 11340718 — intervention group
Group type: COMPARATOR
Intervention: No mouthrinse
Number of subjects: 414
Study 9154757 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary injection of 15 micrograms acetylcholine chloride
Number of subjects: 29
Study 7957035 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin (1.5 g twice daily)
Number of subjects: 45
Study 7957035 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 7957035 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin (continued for at least 35 weeks)
Number of subjects: 45
Study 7957035 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin
Number of subjects: 45
Study 3331395 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.36 mg/kg/day for 9 days (group S)
Number of subjects: 24
Study 3331395 — intervention group
Group type: COMPARATOR
Intervention: No treatment (group NS)
Number of subjects: 24
Study 3331395 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (group S)
Number of subjects: 24
Study 28560756 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing care plan applied using NANDA, NOC, and NIC linkages for 12 weeks
Number of subjects: 0
Study 28560756 — intervention group
Group type: COMPARATOR
Intervention: Control group (specific intervention not mentioned)
Number of subjects: 0
Study 28448225 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Thinking Training (PTT) online intervention
Number of subjects: 0
Study 28448225 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 25559324 — intervention group
Group type: COMPARATOR
Intervention: PegIFN/RBV plus placebo (arm 1)
Number of subjects: 652
Study 25559324 — intervention group
Group type: EXPERIMENTAL
Intervention: PegIFN/RBV plus faldaprevir (120 mg, once daily for 12 or 24 weeks) (arm 2)
Number of subjects: 652
Study 25559324 — intervention group
Group type: EXPERIMENTAL
Intervention: PegIFN/RBV plus faldaprevir (240 mg, once daily for 12 weeks) (arm 3)
Number of subjects: 652
Study 23007137 — intervention group
Group type: EXPERIMENTAL
Intervention: Active stretching program (12 weeks, 3 days/week, 180 seconds daily)
Number of subjects: 138
Study 23007137 — intervention group
Group type: COMPARATOR
Intervention: Control (no stretching)
Number of subjects: 138
Study 20655261 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM
Number of subjects: 2831
Study 20655261 — intervention group
Group type: COMPARATOR
Intervention: MenACWY-D
Number of subjects: 2831
Study 20655261 — intervention group
Group type: COMPARATOR
Intervention: MPSV4
Number of subjects: 2831
Study 19205171 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser stimulation treatment (5 mV, 650 nm, 20 minutes daily for 3 months)
Number of subjects: 46
Study 19205171 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 46
Study 17190951 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A
Number of subjects: 0
Study 14598939 — intervention group
Group type: EXPERIMENTAL
Intervention: ST regimen (streptomycin 1 g/day i.m. for 15 days and tetracycline‐HCl 500 mg every 6 h orally for 45 days)
Number of subjects: 102
Study 14598939 — intervention group
Group type: EXPERIMENTAL
Intervention: SD regimen (streptomycin 1 g/day i.m. for 15 days and doxycycline 100 mg every 12 h orally for 45 days)
Number of subjects: 102
Study 14598939 — intervention group
Group type: EXPERIMENTAL
Intervention: DR regimen (doxycycline 100 mg every 12 h orally for 45 days and rifampicin 15 mg/kg per day in a single morning dose orally for 45 days)
Number of subjects: 102
Study 14598939 — intervention group
Group type: EXPERIMENTAL
Intervention: OR regimen (ofloxacin 200 mg every 12 h orally for 45 days and rifampicin 15 mg/kg per day in a single morning dose orally for 45 days)
Number of subjects: 102
Study 14598939 — intervention group
Group type: EXPERIMENTAL
Intervention: SDR regimen (streptomycin 1 g/day i.m. for 15 days and doxycycline 100 mg every 12 h orally for 45 days plus rifampicin 15 mg/kg per day in a single morning dose orally for 45 days)
Number of subjects: 102
Study 11379605 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose interferon (3 MU day‐1, twice weekly for 6 months)
Number of subjects: 95
Study 11379605 — intervention group
Group type: COMPARATOR
Intervention: Observation alone
Number of subjects: 95
Study 9231885 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (a nitric oxide donor) during experimentally induced migraine crisis
Number of subjects: 50
Study 9231885 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (a nitric oxide donor) during spontaneous migraine attack
Number of subjects: 50
Study 9231885 — intervention group
Group type: COMPARATOR
Intervention: Control groups (healthy subjects and episodic tension headache patients)
Number of subjects: 50
Study 7911286 — intervention group
Group type: EXPERIMENTAL
Intervention: acrivastine (8 mg)
Number of subjects: 24
Study 7911286 — intervention group
Group type: EXPERIMENTAL
Intervention: terfenadine (120 mg)
Number of subjects: 24
Study 7911286 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study 3074300 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 30
Study 3074300 — intervention group
Group type: COMPARATOR
Intervention: Control (Placebo)
Number of subjects: 30
Study 31627907 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-tracer (isotopic and dye) technique for sentinel lymph node identification
Number of subjects: 0
Study 31627907 — intervention group
Group type: COMPARATOR
Intervention: Sentinel lymph node identification
Number of subjects: 0
Study 31345792 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF-mobilized blood stem cell (G-PB) grafts
Number of subjects: 410
Study 31345792 — intervention group
Group type: COMPARATOR
Intervention: Bone marrow (BM) grafts
Number of subjects: 410
Study 28050795 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible cystoscopy
Number of subjects: 100
Study 28050795 — intervention group
Group type: COMPARATOR
Intervention: Rigid cystoscopy
Number of subjects: 100
Study 26266385 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon Plasma Coagulation (APC) along with distilled water injection
Number of subjects: 116
Study 26266385 — intervention group
Group type: COMPARATOR
Intervention: Distilled water injection alone
Number of subjects: 116
Study 22806264 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-subvastus approach
Number of subjects: 40
Study 22806264 — intervention group
Group type: COMPARATOR
Intervention: Standard medial parapatellar approach
Number of subjects: 40
Study 21810044 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 500 mg PLC
Number of subjects: 24
Study 21810044 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 1000 mg PLC
Number of subjects: 24
Study 21810044 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple doses of 500 mg PLC twice a day over 7 days
Number of subjects: 24
Study 21810044 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple doses of 1000 mg PLC twice a day over 7 days
Number of subjects: 24
Study 19654097 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 0
Study 19654097 — intervention group
Group type: COMPARATOR
Intervention: Continued medical management (proton pump inhibitors)
Number of subjects: 0
Study 17116604 — intervention group
Group type: EXPERIMENTAL
Intervention: < 25% expected injury guidance
Number of subjects: 2610
Study 17116604 — intervention group
Group type: EXPERIMENTAL
Intervention: 25%-49% expected injury guidance
Number of subjects: 2610
Study 15599861 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant radiotherapy and chemotherapy (RT-CT) - 226 patients; 70 Gy in 35 fractions with three cycles of a 4-day regimen comprising carboplatin and 5-fluorouracil (5FU)
Number of subjects: 494
Study 15599861 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated radiotherapy (RT) - 268 patients; 64 Gy in 3 weeks
Number of subjects: 494
Study 15599861 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy (RT) - 70 Gy in 35 fractions
Number of subjects: 494
Study 10669274 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia followed by an infusion of normal saline (Control)
Number of subjects: 60
Study 10669274 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia with continuous epidural infusion of 2% lidocaine (Group II)
Number of subjects: 60
Study 10669274 — intervention group
Group type: EXPERIMENTAL
Intervention: General anaesthesia with K+M+B administered 10 min after 2% lidocaine injection and 30 min before skin incision (Group III)
Number of subjects: 60
Study 8659355 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary signs
Number of subjects: 74
Study 8659355 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary signs
Number of subjects: 74
Study 8659355 — intervention group
Group type: EXPERIMENTAL
Intervention: Both primary and secondary signs
Number of subjects: 74
Study 8659355 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary signs (specific signs identified)
Number of subjects: 74
Study 1307517 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled aerosol of platelet activating factor (PAF)
Number of subjects: 0
Study 1307517 — intervention group
Group type: COMPARATOR
Intervention: Chlorpheniramine
Number of subjects: 0
Study 3834227 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuprophane (CUP) membrane
Number of subjects: 0
Study 3834227 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyacrilonitrile (PAN) membrane
Number of subjects: 0
Study 3834227 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0
Study 3834227 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro treatment with CUP membrane fragments
Number of subjects: 0
Study 31578841 — intervention group
Group type: EXPERIMENTAL
Intervention: QFit (Quercetin Phytosome) + Standard Management (SM)
Number of subjects: 0
Study 31578841 — intervention group
Group type: COMPARATOR
Intervention: Standard Management (SM)
Number of subjects: 0
Study 31578841 — intervention group
Group type: EXPERIMENTAL
Intervention: QFit (Quercetin Phytosome)
Number of subjects: 0
Study 30010706 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated self-affirmation and implementation intentions
Number of subjects: 293
Study 30010706 — intervention group
Group type: COMPARATOR
Intervention: Self-affirmation only
Number of subjects: 293
Study 30010706 — intervention group
Group type: COMPARATOR
Intervention: Implementation intentions only
Number of subjects: 293
Study 30010706 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 293
Study 25336052 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser scanning for ankle-foot orthoses production
Number of subjects: 0
Study 25336052 — intervention group
Group type: COMPARATOR
Intervention: Traditional plaster casting for ankle-foot orthoses production
Number of subjects: 0
Study 24324048 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination of perindopril-indapamide (4/1.25 mg)
Number of subjects: 11140
Study 24324048 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11140
Study 23231863 — intervention group
Group type: EXPERIMENTAL
Intervention: Assortment structure with 75% healthy snacks
Number of subjects: 250
Study 23231863 — intervention group
Group type: COMPARATOR
Intervention: Assortment structure with 25% healthy snacks
Number of subjects: 250
Study 23231863 — intervention group
Group type: EXPERIMENTAL
Intervention: Shelf arrangement with healthy snacks at top shelves
Number of subjects: 250
Study 23231863 — intervention group
Group type: COMPARATOR
Intervention: Shelf arrangement with healthy snacks at lower shelves
Number of subjects: 250
Study 23231863 — intervention group
Group type: EXPERIMENTAL
Intervention: Field study sales data
Number of subjects: 250
Study 21148615 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed (500 mg/m² i.v. every 21 days until disease progression)
Number of subjects: 663
Study 21148615 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus best supportive care
Number of subjects: 663
Study 17702126 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term peroral anticoagulation treatment for 6 to 12 months
Number of subjects: 0
Study 17702126 — intervention group
Group type: COMPARATOR
Intervention: Three-month treatment period
Number of subjects: 0
Study 17702126 — intervention group
Group type: EXPERIMENTAL
Intervention: D-dimer detection test
Number of subjects: 0
Study 16779201 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based computer-assisted education (CO-ED) system
Number of subjects: 22
Study 16779201 — intervention group
Group type: COMPARATOR
Intervention: Searching the Internet
Number of subjects: 22
Study 12188443 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzbromarone 100 mg/day
Number of subjects: 14
Study 12188443 — intervention group
Group type: COMPARATOR
Intervention: Allopurinol 300 mg/day
Number of subjects: 14
Study 12188443 — intervention group
Group type: COMPARATOR
Intervention: Comparison of benzbromarone to allopurinol
Number of subjects: 14
Study 10669897 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen A: four tablets at 0, 8, 24 and 48 h (320 mg artemether, 1,920 mg benflumetol)
Number of subjects: 39
Study 10669897 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen B: two tablets at 0, 8, 24 and 48 h (160 mg artemether, 960 mg benflumetol)
Number of subjects: 39
Study 10669897 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen C: four tablets at 0, 8 and 24 h (240 mg artemether, 1,440 mg benflumetol)
Number of subjects: 39
Study 9534283 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. isoproterenol infusion (low doses)
Number of subjects: 10
Study 9534283 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. isoproterenol infusion (higher doses)
Number of subjects: 10
Study 9534283 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 10
Study 9534283 — intervention group
Group type: COMPARATOR
Intervention: Atropine
Number of subjects: 10
Study 9534283 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak exercise
Number of subjects: 10
Study 9534283 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal sinus arrhythmia
Number of subjects: 10
Study 1722935 — intervention group
Group type: EXPERIMENTAL
Intervention: barucainide (300-400 mg/day)
Number of subjects: 10
Study 1722935 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study 1722935 — intervention group
Group type: EXPERIMENTAL
Intervention: barucainide
Number of subjects: 10
Study 6799558 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose and insulin
Number of subjects: 19
Study 6799558 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose, insulin and amino acids
Number of subjects: 19
Study 6799558 — intervention group
Group type: EXPERIMENTAL
Intervention: TPN (Total Parenteral Nutrition)
Number of subjects: 19
Study 6799558 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acids
Number of subjects: 19
Study 6799558 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy supply >120-130% of daily energy output
Number of subjects: 19
Study 30094693 — intervention group
Group type: EXPERIMENTAL
Intervention: weekday-on and weekend-off regimen
Number of subjects: 58
Study 30094693 — intervention group
Group type: COMPARATOR
Intervention: conventional schedule
Number of subjects: 58
Study 28236539 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal mammary node irradiation (IMNI)
Number of subjects: 747
Study 28236539 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard and partial wide tangents RT techniques
Number of subjects: 747
Study 28236539 — intervention group
Group type: COMPARATOR
Intervention: Arm 2 (IMNI group)
Number of subjects: 747
Study 27052991 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanconone® (1000 mg)
Number of subjects: 72
Study 27052991 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen (400 mg)
Number of subjects: 72
Study 24099724 — intervention group
Group type: EXPERIMENTAL
Intervention: Two green kiwifruit/day plus healthy diet
Number of subjects: 85
Study 24099724 — intervention group
Group type: COMPARATOR
Intervention: Healthy diet alone
Number of subjects: 85
Study 23147979 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary foods in addition to breast milk from age 4 months (CF)
Number of subjects: 119
Study 23147979 — intervention group
Group type: COMPARATOR
Intervention: Exclusive breastfeeding for 6 months (EBF)
Number of subjects: 119
Study 20335546 — intervention group
Group type: EXPERIMENTAL
Intervention: High-heat-treated diet
Number of subjects: 62
Study 20335546 — intervention group
Group type: COMPARATOR
Intervention: Steamed diet
Number of subjects: 62
Study 18833115 — intervention group
Group type: EXPERIMENTAL
Intervention: Stalevo
Number of subjects: 0